Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms

1997 ◽  
Vol 74 (1) ◽  
pp. 45-48 ◽  
Author(s):  
T. Budak-Alpdoğan ◽  
Z. Demirçay ◽  
Ö. Alpdoğan ◽  
H. Direskeneli ◽  
T. Ergun ◽  
...  
2006 ◽  
Vol 47 (12) ◽  
pp. 2674-2675 ◽  
Author(s):  
Seray Külcü Çakmak ◽  
Ülker Gül ◽  
Arzu Kiliç ◽  
Müzeyyen Gönül ◽  
Seçil Soylu ◽  
...  

Seizure ◽  
2008 ◽  
Vol 17 (8) ◽  
pp. 744-747 ◽  
Author(s):  
Elisabeth Chroni ◽  
Alexandra Monastirli ◽  
Panayiotis Polychronopoulos ◽  
Efi Pasmatzi ◽  
Sophia Georgiou ◽  
...  

2021 ◽  
pp. 1-10
Author(s):  
Asmaa Kamal ◽  
Fatema T Elgengehy ◽  
Zahraa Elawady ◽  
Nahla A. Fawzy ◽  
Ola El Sisi

2021 ◽  
Vol 16 (S1) ◽  
Author(s):  
Isabelle Kone-Paut ◽  
◽  
Stéphane Barete ◽  
Bahram Bodaghi ◽  
Kumaran Deiva ◽  
...  

AbstractBehçet’s disease (BD) is a systemic variable vessel vasculitis that involves the skin, mucosa, joints, eyes, arteries, veins, nervous system and gastrointestinal system, presenting with remissions and exacerbations. It is a multifactorial disease, and several triggering factors including oral cavity infections and viruses may induce inflammatory attacks in genetically susceptible individuals. BD vasculitis involves different vessel types and sizes of the vascular tree with mixed-cellular perivascular infiltrates and is often complicated by recurrent thrombosis, particularly in the venous compartment. Several new therapeutic modalities with different mechanisms of action have been studied in patients with BD. A substantial amount of new data have been published on the management of BD, especially with biologics, over the last years. These important therapeutic advances in BD have led us to propose French recommendations for the management of Behçet’s disease [Protocole National de Diagnostic et de Soins de la maladie de Behçet (PNDS)]. These recommendations are divided into two parts: (1) the diagnostic process and initial assessment; (2) the therapeutic management. Thirty key points summarize the essence of the recommendations. We highlighted the main differential diagnosis of BD according to the type of clinical involvement; the role of genetics is also discussed, and we indicate the clinical presentations that must lead to the search for a genetic cause.


2017 ◽  
Vol 6 (7) ◽  
pp. 74 ◽  
Author(s):  
Yuki Nanke ◽  
Toru Yago ◽  
Shigeru Kotake

Sign in / Sign up

Export Citation Format

Share Document